Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87–108.
Article
Google Scholar
Edgren G, Adami HO, Weiderpass E, et al.A global assessment of the oesophageal adenocarcinoma epidemic. Gut. 2013; 62(10):1406–14.
Article
Google Scholar
CRUK. Cancer Statistics for the UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics. Accessed 19 Aug 2019.
Cunningham D, Allum WH, Stenning SP, et al.Perioperative chemotherapy versus surgery alone for resectable oesophagogastric cancer. N Engl J Med. 2006; 355(1):11–20.
Article
CAS
Google Scholar
MRC. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319):1727–33.
Article
Google Scholar
van Hagen P, Hulshof MC, van Lanschot JJ, et al.Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22):2074–84.
Article
CAS
Google Scholar
Cunningham D, Starling N, Rao S, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358(1):36–46.
Article
CAS
Google Scholar
Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006; 24(31):4991–7.
Article
CAS
Google Scholar
Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, Liu T, Schenker M. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. 2020; 31:S1191.
Article
Google Scholar
Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687–97.
Article
CAS
Google Scholar
Ford HE, Marshall A, Bridgewater JA, et al.Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15(1):78–86.
Article
CAS
Google Scholar
Kang JH, Lee SI, Lim DH, et al.Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13):1513–8.
Article
CAS
Google Scholar
Fuchs CS, Tomasek J, Yong CJ, et al.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383(9911):31–39.
Article
CAS
Google Scholar
Wilke H, Muro K, Van Cutsem E, et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15(11):1224–35.
Article
CAS
Google Scholar
Robert C, Schachter J, Long GV, et al.Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372(26):2521–32.
Article
CAS
Google Scholar
Larkin J, Chiarion-Sileni V, Gonzalez R, et al.Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23–34.
Article
Google Scholar
Brahmer J, Reckamp KL, Baas P, et al.Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123–35.
Article
CAS
Google Scholar
Rosenberg JE, Hoffman-Censits J, Powles T, et al.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909–20.
Article
CAS
Google Scholar
Motzer RJ, Escudier B, McDermott DF, et al.Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803–13.
Article
CAS
Google Scholar
Kang Y-K, Satoh T, Ryu M-H, et al.Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. J Clin Oncol. 2017; 35(4_suppl):2.
Article
Google Scholar
Janjigian YY, Bendell J, Calvo E, et al.CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol. 2018; 36(28):2836–44.
Article
CAS
Google Scholar
Fuchs CS, Doi T, Jang RW, et al.Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Oesophagogastric Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018; 4(5):e180013.
Article
Google Scholar
Shitara K, Ozguroglu M, Bang YJ, et al.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018; 392(10142):123–33.
Article
CAS
Google Scholar
Tabernero J, Van Cutsem E, Bang Y, et al.LBA-002 Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or oesophagogastric junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Ann Oncol. 2019; 30(Supplement_4):mdz183.001.
Google Scholar
Kim ST, Cristescu R, Bass AJ, et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449–58.
Article
CAS
Google Scholar
Hochhauser D, Glynne-Jones R, Potter V, et al.A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013; 12(5):809–18.
Article
CAS
Google Scholar
Pietrantonio F, Perrone F, de Braud F, et al.Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. Ann Oncol. 2014; 25(2):404–8.
Article
CAS
Google Scholar
Germano G, Lamba S, Rospo G, et al.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature. 2017; 552(7683):116–20.
Article
CAS
Google Scholar
Banissi C, Ghiringhelli F, Chen L, et al.Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009; 58(10):1627–34.
Article
CAS
Google Scholar
Ellsworth S, Balmanoukian A, Kos F, et al.Sustained CD4(+) T cell-driven lymphopenia without a compensatory IL-7/IL-15 response among high-grade glioma patients treated with radiation and temozolomide. Oncoimmunology. 2014; 3(1):e27357.
Article
Google Scholar
Fadul CE, Fisher JL, Gui J, et al.Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol. 2011; 13(4):393–400.
Article
CAS
Google Scholar
Grossman SA, Ye X, Lesser G, et al.Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011; 17(16):5473–80.
Article
CAS
Google Scholar
Karachi A, Yang C, Dastmalchi F, et al.Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019; 21(6):730–41.
Article
CAS
Google Scholar
Ouyang M, White EE, Ren H, et al.Metronomic Doses of Temozolomide Enhance the Efficacy of Carbon Nanotube CpG Immunotherapy in an Invasive Glioma Model. PLoS ONE. 2016; 11(2):e0148139.
Article
Google Scholar
Sampson JH, Aldape KD, Archer GE, et al.Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011; 13(3):324–33.
Article
CAS
Google Scholar
A’Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001; 20(6):859–66.
Article
Google Scholar
Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26(4):404–13.
Article
Google Scholar
Lee LYW, Cazier J-B, Starkey T, et al.COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020; 21(10):1309–16.
Article
CAS
Google Scholar
Chan A-W, Tetzlaff JM, Altman DG, Laupacis A. Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158:200–7.
Article
Google Scholar